Literature DB >> 24821290

[Differential diagnostics of Parkinson's disease with nuclear medicine procedures].

P T Meyer1, F Amtage, S Hellwig.   

Abstract

Early differential diagnosis of parkinsonism is of paramount therapeutic and prognostic importance. In the present review, the diagnostic value of routinely used nuclear medicine procedures is presented and critically discussed. The [(123)I]FP-CIT single-photon emission computed tomography (SPECT) is the method of choice for differentiation between neurodegenerative and non-neurodegenerative parkinsonism. The [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) method provides a very high diagnostic accuracy for differentiating between Parkinson's disease (PD) and atypical Parkinsonian syndromes (APS), which is clearly superior to the accuracy of [(123)I]FP-CIT SPECT, [(123)I]IBZM SPECT and [(123)I]MIBG scintigraphy. Furthermore, [(18)F]FDG-PET is the only of the aforementioned techniques that also allows a reliable differentiation between APS subgroups (e.g., multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration). Current studies are investigating the probable value of [(18)F]FDG-PET for risk stratification of dementia in PD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24821290     DOI: 10.1007/s00115-013-3995-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  48 in total

1.  123I-iodobenzamide SPECT is not an independent predictor of dopaminergic responsiveness in patients with suspected atypical parkinsonian syndromes.

Authors:  Sabine Hellwig; Annabelle Kreft; Florian Amtage; Oliver Tüscher; Oliver H Winz; Bernhard Hellwig; Cornelius Weiller; Wolfgang A Weber; Werner Vach; Philipp T Meyer
Journal:  J Nucl Med       Date:  2013-10-10       Impact factor: 10.057

2.  Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration.

Authors:  Stefanie Klaffke; Andrea A Kuhn; Michail Plotkin; Holger Amthauer; Daniel Harnack; Roland Felix; Andreas Kupsch
Journal:  Mov Disord       Date:  2006-10       Impact factor: 10.338

3.  FDG PET in the differential diagnosis of parkinsonian disorders.

Authors:  Thomas Eckert; Anna Barnes; Vijay Dhawan; Steve Frucht; Mark F Gordon; Andrew S Feigin; D Eidelberg
Journal:  Neuroimage       Date:  2005-04-26       Impact factor: 6.556

Review 4.  The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes.

Authors:  S Braune
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

5.  123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  A Antonini; R Benti; R De Notaris; S Tesei; A Zecchinelli; G Sacilotto; N Meucci; M Canesi; C Mariani; G Pezzoli; P Gerundini
Journal:  Neurol Sci       Date:  2003-10       Impact factor: 3.307

6.  Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.

Authors:  Kenji Ishibashi; Yuko Saito; Shigeo Murayama; Kazutomi Kanemaru; Keiichi Oda; Kiichi Ishiwata; Hidehiro Mizusawa; Kenji Ishii
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

7.  123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.

Authors:  J Schwarz; K Tatsch; G Arnold; M Ott; C Trenkwalder; C M Kirsch; W H Oertel
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

8.  Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.

Authors:  K Stiasny-Kolster; Y Doerr; J C Möller; H Höffken; T M Behr; W H Oertel; G Mayer
Journal:  Brain       Date:  2004-11-17       Impact factor: 13.501

9.  Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes.

Authors:  Gaëtan Garraux; Christophe Phillips; Jessica Schrouff; Alexandre Kreisler; Christian Lemaire; Christian Degueldre; Christian Delcour; Roland Hustinx; André Luxen; Alain Destée; Eric Salmon
Journal:  Neuroimage Clin       Date:  2013-06-14       Impact factor: 4.881

Review 10.  Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.

Authors:  Nin Bajaj; Robert A Hauser; Igor D Grachev
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-13       Impact factor: 10.154

View more
  2 in total

Review 1.  [Helpful instrumental examinations in idiopathic Parkinson's disease].

Authors:  U Walter; H Zach; I Liepelt-Scarfone; W Maetzler
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

2.  The Hamburg Parkinson day-clinic: a new treatment concept at the border of in- and outpatient care.

Authors:  Odette Fründt; Tina Mainka; Beate Schönwald; Bianca Müller; Polina Dicusar; Christian Gerloff; Carsten Buhmann
Journal:  J Neural Transm (Vienna)       Date:  2018-08-22       Impact factor: 3.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.